## ACLX: Arcellx, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -7.3% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($56.90)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bearish (Bullish: 0, Bearish: 1)

**1. Voya Investment Management LLC Reduces Stock Holdings in Arcellx, Inc. $ACLX**
- Source: MarketBeat | 20251222T130958 | Bearish | Relevance: 100%
- Voya Investment Management LLC recently reduced its stake in Arcellx, Inc. (NASDAQ:ACLX) by 10.3% in the third quarter, selling over 28,000 shares. This reduction aligns with Arcellx's weak quarterly results, which missed both EPS and revenue estimates, alongside recent insider selling activity. Despite these factors, institutional ownership of Arcellx remains high at over 96%.

**2. Arcellx, Inc. (NASDAQ:ACLX) Given Average Recommendation of "Moderate Buy" by Analysts**
- Source: MarketBeat | 20251220T070920 | Neutral | Relevance: 100%
- Arcellx, Inc. (NASDAQ:ACLX) has received a consensus "Moderate Buy" rating from ten brokerages, with an average 12-month price target of $115.71. Despite missing Q3 earnings and revenue estimates, institutional investors have shown increased interest, with hedge funds and other institutions owning 96.03% of the stock. Insiders, however, sold 33,843 shares, reducing their ownership to 8.35%.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-22 | Wells Fargo | $100 | $0 | 0% |
| 2025-12-08 | Canaccord Genui | $130 | $130 | 0% |
| 2025-12-08 | Needham | $105 | $105 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-22 | Wells Fargo | init | Overweight |
| 2025-12-08 | Canaccord Genui | main | Buy |
| 2025-12-08 | Needham | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 7 ($2.46M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 1 / 5 |

**Top Holders:**
- Gilead Sciences Inc: 11.6% (0.0%)
- T. Rowe Price Invest: 11.0% (+226.8%)
- FMR, LLC: 10.0% (-3.5%)
- Paradigm Biocapital : 8.0% (0.0%)
- Vanguard Group Inc: 6.8% (-1.0%)

### Key Risks

1. High short interest (15.2%, 7.7 days to cover): squeeze risk or crowded bearish bet.
2. Long-term trend broken: trading 8.9% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Balance sheet: strong liquidity (4.0x), low leverage (D/E 0.49). Revenue growth strong at 242% YoY. Insider selling cluster ($2.5M in 90 days), potential headwind. Institutional flow bullish (1 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.8B |
| Beta | 0.34 |
| 52W Range | $47.86 - $94.07 |
| Short Interest | 15.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 strengthening from -11.6% to -7.3% (+4.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 11.3pp (needs >4.0% for momentum thesis). AM_20 at -6.8% indicates price below own 20MA trend. Underperforming sector by 7.2pp, stock-specific weakness. Below SMA200 (0.91x), long-term trend not supportive. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -7.29% (CS: 3) | Weak |
| RSI_14 | 34.0 | Neutral |
| MACD Histogram | -0.36 | Bearish |
| vs SMA20 | 0.932x | Below |
| vs SMA50 | 0.808x | Below |
| vs SMA200 | 0.911x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $65.18
- **Stop Loss:** $56.90 (12.7% risk)
- **Target:** $73.46 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 144
- **Position Value:** $9,385.92
- **Portfolio %:** 9.39%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-26 (Est: $-1.06)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.03 | $-0.99 | +4.1% |
| 2025Q2 | $-1.03 | $-0.94 | +8.9% |
| 2025Q1 | $-0.74 | $-1.13 | -53.0% |
| 2024Q4 | $-0.47 | $-0.87 | -83.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*